In acute bipolar mania trials, the proportions of patients with transaminase elevations of times the upper limits of the normal reference range in pool of 3- to 12-week placebo-controlled trials were approximately for both SEROQUEL and placebo. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Outside the weekly lab tests, the clients who used this drug were remarkedly better than when they used some of the new drugs. The risk of orthostatic hypotension is about in 100 one of every hundred patients who takes quetiapine. Schizophrenia The efficacy of SEROQUEL in the treatment of schizophrenia was established in short-term 6-week controlled trials of inpatients with schizophrenia who met DSM III-R criteria for schizophrenia. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia. One exception is tamoxifen, which, like lithium and valproate, inhibits protein kinase and was found to have antimanic efficacy superior to canadian quetiapine sin receta placebo.